جستجوی استاد راهنمای دانشگاهی

• Microbiology
• Infectious Diseases
• Cell Biology
• +۷ مورد دیگر

Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.

Laura Soltمشاهده پروفایل

دانشیار

• Autoimmune Disease
• Cancer Immunotherapy
• Immunometabolism
• +۵ مورد دیگر

Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.

• Drug Delivery
• Pharmaceutics
• Nanomedicine
• +۵ مورد دیگر

Caitriona M. O'Driscoll is Professor and Chair of Pharmaceutics at University College Cork's School of Pharmacy, Ireland. With over four decades of academic experience, she previously served as Head of the School of Pharmacy at UCC from 2003-2009 and 2010-2013. Her established drug delivery research team spans from pre-formulation through to production and manufacture of prototype delivery systems suitable for clinical trial, with strong industry links underpinning many research projects. Her research interests focus on translational drug delivery with emphasis on 'problem' drugs including poorly water soluble compounds and biopharmaceuticals like peptide/protein drugs, plasma DNA and siRNA. She develops nano-sized delivery constructs that are robust enough to survive processing, stable on storage, and achieve cell/site specific delivery in vivo. Greater than 40% of new chemical entities are poorly water soluble Biopharmaceuticals now approach 50% of all new drugs in development Major barrier is design of efficient delivery systems Special focus on oral drug delivery despite challenges Analysis of her recent publications reveals a strong emphasis on targeted nanodelivery systems for cancer therapy, particularly prostate and colorectal cancer, as well as neurodegenerative diseases like Huntington's. Her work demonstrates expertise in cyclodextrin-based nanoparticles, siRNA delivery, and disease-specific formulations that account for conditions like Crohn's disease that affect drug delivery. Scientific awards include: 'Person of the Year award' by Parenteral Drug Association (Ireland Chapter) in 2013 'Award for Professional Excellence' by Helix Health in 2007/2008 'Award for Pharmacist of the Year' by Helix Health in 2007/2008 With €10.5M in career research income and 25 PhDs graduated, Professor O'Driscoll's work has attracted funding from diverse sources including Science Foundation Ireland, Enterprise Ireland, and industry partners. Her research group maintains strong links with Pharmaceutical Chemistry and Process & Chemical Engineering at UCC, creating a unique strength for drug development research from design through to clinical trial. She has served as external examiner for multiple universities and as PhD thesis examiner at institutions worldwide. Her research team operates within UCC's drug delivery group, which has established expertise spanning from pre-formulation through to production and manufacture of prototype delivery systems. The group maintains strong industry connections and offers various PhD positions, focusing particularly on translational research with product-driven applications.

Jeffrey Beekmanمشاهده پروفایل

استاد

• Cystic Fibrosis
• Regenerative Medicine
• Stem Cell Research
• +۵ مورد دیگر

Jeffrey Beekman is a Full Professor at the University Medical Center Utrecht, specializing in translational research for chronic diseases through the Department of Pediatric Pulmonology. His work bridges basic and clinical research to develop novel diagnostics and therapeutics for conditions like cystic fibrosis (CF) and Primary Ciliary Dyskinesia. Education: PhD in Molecular Immunology (2004) Key Roles: Principle Investigator since 2010, co-founder of FAIR Therapeutics, Board Member of the Dutch Society for Stem Cell Research His research focuses on patient-derived organoid models to study disease mechanisms, validate therapeutic targets, and optimize drug development. Strategic programs include Child Health and Regenerative Medicine & Stem Cells . Recent publications highlight his work on CFTR gene therapy, organoid-based drug efficacy testing, and host-pathogen interactions in CF. Collaborations span molecular biology, clinical pulmonology, and biotech translation. Key Techniques: Organoid modeling, RNA sequencing, Forskolin-induced swelling assay Diseases Studied: Cystic Fibrosis, Colorectal Cancer Susceptibility, Primary Ciliary Dyskinesia

• Immunology
• Gastroenterology
• Mucosal Immunology
• +۳ مورد دیگر

Mahima Swamy is a Principal Investigator and Wellcome Trust Sir Henry Dale Fellow at the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) at the University of Dundee. Her research focuses on understanding immune interactions at the intestinal epithelium, particularly the role of intraepithelial lymphocytes (IEL) in maintaining gut homeostasis and resisting infections. She leads a lab investigating IEL biology, including their regulation by PIM kinases and LRRK2 in inflammatory bowel diseases (IBD) and Crohn’s disease. Dr. Swamy earned her BSc in Biological Sciences from BITS Pilani and completed her PhD at the Max-Planck Institute in Freiburg, Germany. She held postdoctoral fellowships at CRUK London Research Institute and the University of Dundee before establishing her independent group in 2016. Her work combines proteomics, mouse models, and in vitro co-cultures to explore IEL signaling pathways and their dysregulation in diseases. Key research interests include: IEL-mediated protection against pathogens, metabolic adaptations of IEL to the gut environment, and the role of LRRK2 in intestinal immune function. Her lab collaborates with the Alessi lab to study LRRK2 inhibitors for IBD therapy. Education: BSc (BITS Pilani) → PhD (MPIIB, Germany) → Postdocs (CRUK, Dundee) Lab Members: Includes PhD students (Rebecca Pemberton, Srishti, Neema Skariah) and postdocs (Amanpreet Chawla, Purbasha Bhattacharya) Collaborations: Tayside Immunology Group, Society for Mucosal Immunology Scientific achievements include discoveries of PIM kinases in IEL function and LRRK2’s role in gut inflammation. Her group has pioneered tools like phospho-proteomic analyses and epithelial organoid:IEL co-cultures.

• Intestinal Homeostasis
• Aging Biology
• Microbial Ecology
• +۳ مورد دیگر

Dr. Rebecca Clark is an Associate Professor in the Department of Biosciences at Durham University. Her research focuses on understanding intestinal function in health and disease using the Drosophila model. She investigates how the intestinal epithelium balances barrier function, nutrient absorption, microbial symbiosis, and cell turnover, particularly during aging and disease states. Key research questions include mechanisms of intestinal barrier failure and the interplay between nutrition and intestinal homeostasis. Her work integrates genetic, microbiological, and physiological approaches to explore aging-related pathologies. Current projects aim to identify molecular pathways linking intestinal health to longevity. Supervised postgraduate students include Ale Acevedo Marcelin, Beñat Yanez, and Fanila Shahzad. Dr. Clark’s lab uses Drosophila as a model system due to its powerful genetic tools and evolutionary relevance. Research has implications for understanding human conditions such as inflammatory bowel disease and age-related metabolic disorders. Recent findings highlight microbiota-independent aging mechanisms and the role of tricellular junctions in stem cell regulation. No scientific awards are explicitly listed in the provided materials. Her research has been published in journals like Cell , Nature Cell Biology , and Proceedings of the National Academy of Sciences .

Ali Nazmiمشاهده پروفایل

استادیار

• Nutritional Immunology
• Mucosal Immunology
• Host-Pathogen Interactions
• +۳ مورد دیگر

Dr. Ali Nazmi is an Assistant Professor in the Department of Animal Sciences and the Food for Health Discovery Theme at The Ohio State University. He holds affiliations within the College of Food, Agricultural, and Environmental Sciences (CFAES). His research focuses on nutritional immunology, host-pathogen interactions in poultry and pigs, and the metabolic roles of intestinal immune cells. Nazmi obtained his B.Sc. in Poultry Production and M.Sc. in Poultry Breeding from Ain Shams University (Egypt), followed by a Ph.D. in Animal Biology from UC Davis (2017). He completed postdoctoral training in mucosal immunology at Vanderbilt University Medical Center before joining OSU in 2021. His recent work includes studies on intraepithelial lymphocytes in intestinal health, enteric disease resistance in poultry, and swine T cell biology. Key publications address mechanisms of necrotic enteritis in chickens, unconventional T cell subsets, and cytokine regulation in colitis models. Collaborations span avian immunology, swine immunology, and semen cryopreservation techniques. Education: B.Sc. (Ain Shams), M.Sc. (Ain Shams), Ph.D. (UC Davis) Postdoc: Vanderbilt University Medical Center (mucosal immunology) Key Research Themes: Nutritional Immunology, Mucosal Immunity, Avian/Porcine Health

Pierre Maechlerمشاهده پروفایل

استاد

• Mitochondrial metabolism
• Beta-cell function
• Diabetes research
• +۵ مورد دیگر

Pierre Maechler is a Professor at the University of Geneva's Faculty of Medicine in the Department of Cell Physiology and Metabolism. His research focuses on mitochondrial metabolism in pancreatic beta cells and its critical role in diabetes pathogenesis, with particular emphasis on glutamate dehydrogenase function and regulation. His laboratory investigates the molecular mechanisms of insulin secretion and beta-cell failure in Type 2 diabetes. Maechler's research interests span mitochondrial metabolism, energy homeostasis, and the molecular pathways linking nutrient sensing to insulin secretion. His work has established crucial connections between glutamate metabolism, beta-cell function, and diabetes development. He investigates how metabolic stressors like glucotoxicity and lipotoxicity impair beta-cell function through mitochondrial dysfunction. His research has expanded to include the role of glutamate dehydrogenase in multiple organs including brain, liver, and muscle, revealing systemic metabolic implications. Analysis of Maechler's publication record shows a sustained focus on beta-cell metabolism with evolving scope. Early work established fundamental mechanisms of glutamate signaling in insulin secretion, while recent publications demonstrate expansion into multi-organ metabolic regulation. His research has identified novel biomarkers for beta-cell mass, explored therapeutic targets for diabetes, and revealed unexpected roles for glutamate dehydrogenase in diverse physiological processes from muscle regeneration to brain function. The consistent thread through his work is understanding how mitochondrial metabolism governs cellular and systemic energy homeostasis. Professor Maechler has mentored numerous PhD students and postdoctoral fellows who have gone on to publish significant work in diabetes research. His laboratory collaborates extensively with clinical researchers to translate basic findings into potential therapeutic approaches for diabetes. Funding for his work likely comes from Swiss National Science Foundation and other European research agencies, supporting investigations into metabolic diseases. Maechler leads the Mitochondria and Energy Metabolism research group at the University of Geneva. His team employs a multidisciplinary approach combining molecular biology, metabolomics, and physiology to investigate metabolic regulation in health and disease. The laboratory maintains strong connections with clinical diabetes researchers, facilitating translational applications of their findings. Current work focuses on identifying novel therapeutic targets for preserving beta-cell function in diabetes.

Amir Sanati Nezhadمشاهده پروفایل

استاد

• Biosensing
• Microfluidics
• Tissue Engineering
• +۶ مورد دیگر

Dr. Amir Sanati Nezhad is a Full Professor in the Department of Biomedical Engineering and Mechanical and Manufacturing Engineering at the University of Calgary's Schulich School of Engineering. He leads the BioMEMS and Bioinspired Microfluidic Laboratory and holds memberships in the Hotchkiss Brain Institute, Snyder Institute for Chronic Diseases, and Arnie Charbonneau Cancer Institute. With a PhD in Mechanical Engineering from Concordia University (2013) and postdoctoral training at Harvard and McGill, he specializes in bioinspired microfluidics, tissue engineering, biosensors, and organ-on-chip technologies. His research focuses on developing point-of-care devices for cancer, brain injury, and infectious disease diagnostics, alongside bioinspired microdevices for disease modeling. He has published over 350 peer-reviewed works and holds prestigious awards like the Canada Research Chair and Governor General’s Gold Medal. His educational background includes degrees from Isfahan University of Technology (B.S., 2006), Amirkabir University (M.S., 2009), and Concordia University (PhD, 2013). Research interests include biosensing, microfluidics, and digital health technologies. Recent articles highlight innovations in wearable biosensors, molecularly imprinted polymers, and self-powered microfluidic systems. His awards reflect contributions to both research and teaching excellence. Grants and collaborations include licensing technologies to diagnostic companies. His lab emphasizes translational research, integrating microfluidics with AI for healthcare applications. He teaches advanced biomedical engineering courses and oversees interdisciplinary projects in organ-on-chip and biomaterials.

Yuuki Obataمشاهده پروفایل

استادیار

• Gut Microbiota Research
• Immune System Regulation
• Enteric Nervous System Development
• +۳ مورد دیگر

Dr. Yuuki Obata is an Assistant Professor in the Department of Immunology and Neuroscience at UT Southwestern Medical Center, USA. He holds an Investigator role at the O'Donnell Brain Institute. Previously, he served as a postdoctoral fellow at the Francis Crick Institute (2016-2021) and the University of Tokyo (2015-2016). His research focuses on how environmental signals (microbiota, diet, circadian rhythms) shape intestinal neural circuits and immune networks. He employs advanced techniques including imaging, viral tracing, gnotobiotic systems, and multi-omics approaches. Education: PhD in Immunology from Chiba University (RIKEN Joint Graduate School Program), Japan. Postdoctoral training included JSPS Superlative Postdoctoral Fellowships (Japan) and EMBO/HFSP fellowships (UK). Research interests span microbiota-immune interactions, enteric nervous system development, gut-brain axis communication, and epigenetic regulation of immune responses. His lab investigates mechanisms linking microbial metabolites to host physiology, particularly in metabolic and neural contexts. Key findings include microbiota's role in IgA responses, T cell differentiation, and neuronal programming. Collaborations emphasize inter-organ communication and translational applications in immunology and neuroscience. Laboratory: The Obata Lab at UT Southwestern employs interdisciplinary methods to address how environmental factors reprogram gut neural and immune systems. Future work includes exploring microbiota-based therapies and neuroimmune interactions in disease models.

Rebecca L. Carrierمشاهده پروفایل

استاد

• Intestinal Tissue Engineering
• Retinal Regenerative Medicine
• Oral Drug Delivery
• +۴ مورد دیگر

Rebecca L. Carrier is a Distinguished Professor in the Department of Chemical Engineering at Northeastern University and affiliated faculty in Bioengineering and Biology. Her research focuses on biological systems-material interactions, spanning intestinal tissue engineering, retinal regenerative medicine, and oral drug delivery. Education: PhD in Chemical Engineering from MIT (2000), BS from Rensselaer Polytechnic Institute (1995) Research Interests: Carrier’s work advances understanding of compound transport in biological systems and develops biomimetic biomaterials. Key areas include lipid impact on oral absorption, mucus barrier mechanics, and retinal/intestinal tissue engineering. The Advanced Drug Delivery Research Lab employs engineering principles to create disease models and therapeutic delivery systems. Publication Trends: Recent articles highlight interdisciplinary approaches to drug transport modeling, mucosal barrier engineering, and biomaterials for organoid culture. Studies integrate chemical engineering, microbiology, and biomedical applications. Scientific Awards: Fellow, Controlled Release Society (2024) Distinguished Faculty Award (2024) AIMBE Fellow (2018) Søren Buus Outstanding Research Award (2017) NSF CAREER Award (2008) Advising & Grants: Carrier advises PhD and capstone design students, including Ronak Ansaripour’s award-winning team. She secured NIH grants for lipid absorption studies and a Spark Fund award for algorithm-driven drug delivery optimization. Collaborations include research with University College Dublin (2024). Labs & Teams: The Advanced Drug Delivery Research Lab (ADDRES) investigates retinal cell transplantation, gut microbiome interactions, and mucosal barrier dynamics. Lab values emphasize diversity, anti-racism, and ethical scientific collaboration.

Virginia Pedicordمشاهده پروفایل

استادیار

• Immunology
• Microbiota
• Host-Pathogen Interaction
• +۴ مورد دیگر

Dr. Virginia Pedicord is a Principal Investigator at the University of Cambridge's Department of Medicine and the Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID). She leads the Pedicord Lab within the Cambridge Immunology Network as a Sir Henry Dale Fellow, a prestigious research fellowship jointly funded by the Royal Society and Wellcome Trust. Her research focuses on understanding the complex interactions between gut microbiota, host immunity, and disease pathogenesis. Dr. Pedicord received her PhD in Immunology and Microbial Pathogenesis from Cornell University under the supervision of Dr. James P. Allison at Memorial Sloan Kettering Cancer Center, where she studied CD8+ T cell biology. She completed her postdoctoral training at the Rockefeller University before joining the University of Cambridge in 2018. Her laboratory employs a multi-disciplinary approach combining functional metagenomics, in vivo models, cellular immunology, transcriptomics, and proteomics to investigate how commensal microbes influence host intestinal and systemic physiology. Research focuses on gut microbiota's role in immune responses and pathogen resistance Investigates how gut microbes and microbial metabolites affect resistance to infection Studies local and systemic T cell responses and gut-brain axis of neuronal function Uses functional metagenomics to identify cellular and molecular targets of microbiota-mediated immunity Dr. Pedicord's recent publications demonstrate a strong focus on how specific gut bacteria like Enterocloster clostridioformis protect against pathogens such as Salmonella, how microbial metabolites enhance cancer immunotherapy, and the role of the microbiome in various disease contexts including pancreatic cancer and inflammatory bowel disease. Her work bridges fundamental microbiome research with potential therapeutic applications. Scientific Recognition: Sir Henry Dale Fellow (2018) Dr. Pedicord's research program aims to provide mechanistic insights into host-microbiota interactions that will advance our understanding of infectious diseases, autoimmune disorders, and cancer, potentially enabling new therapeutic approaches. Her laboratory is situated at the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus.

Stephanie Langelمشاهده پروفایل

استادیار

• Mucosal Immunology
• Viral Immunology
• Maternal-Neonatal Health
• +۴ مورد دیگر

Overview Dr. Stephanie Langel is an Assistant Professor in the Department of Pathology at Case Western Reserve University School of Medicine, with a joint appointment in the Center for Global Health and Diseases. Her research focuses on mucosal immune responses, particularly IgA antibodies at maternal-neonatal interfaces and their role in protecting against viral pathogens like influenza, rotavirus, and SARS-CoV-2. She leads a multidisciplinary team using single-cell technologies, animal models, and human clinical samples. Education PhD in Virology/Immunology from The Ohio State University (2018), MS in Immunology from Virginia Tech (2013), BS in Animal Sciences from The Ohio State University (2011). Research Interests Maternal immunization strategies to boost breast milk immunity Mechanisms of maternal antibody interference in vaccine responses Mucosal immunization to block airborne virus transmission IgA immunobiology in the female reproductive tract Publications & Awards Over 20 peer-reviewed publications, including high-impact journals like Cell Host & Microbe and Mucosal Immunology . Recognized with awards including the 2022 Distinguished Alumni Award and Seed Fund Award. Active in professional societies like the Society for Mucosal Immunology. Labs & Collaborations Langel Research Team at the Center for Global Health and Diseases. Collaborates on projects involving mucosal immunity, maternal-neonatal health, and vaccine development for respiratory viruses.

• Immunology
• Molecular Immunology
• T cell biology
• +۵ مورد دیگر

Brigitta Stockinger is a distinguished Professor at the Francis Crick Institute, leading research in the Division of Molecular Immunology. With a career spanning over three decades, she has established herself as a leading authority in immunology, particularly in the study of T cell biology and the aryl hydrocarbon receptor (AHR) pathway. PhD in Biology from the University of Mainz Postdoctoral training in London, Cambridge, and Heidelberg Member of the Basel Institute for Immunology (1985-1991) Group leader at MRC National Institute for Medical Research (1991-present, now part of Francis Crick Institute) Head of Division of Molecular Immunology (2010-present) Professor Stockinger's research has evolved from studying immune tolerance using T cell receptor transgenic mouse models to pioneering work on immunological memory with CD4 memory T cells. Her lab made seminal discoveries regarding Th17 cell differentiation factors, which led to groundbreaking research on the aryl hydrocarbon receptor (AHR) as an environmental sensor in the immune system. Her work spans fundamental immunology, infection responses, inflammation, and the intersection of environmental factors with immune regulation. Analysis of her extensive publication record (over 65 Crick publications) reveals a strong focus on Immunology (38 publications), followed by Model Organisms (12), Genetics & Genomics (10), and Tumour Biology (9). Her most influential work appears in top journals including Nature (5 papers), Nature Immunology (6 papers), and Immunity (6 papers), demonstrating the high impact of her research on understanding T cell plasticity, AHR signaling, and mucosal immunity. Fellow of the Academy of Medical Sciences (2005) EMBO fellow (2008) Fellow of the Royal Society (2013) ERC Advanced Investigator grant (2009) Wellcome Senior Investigator Grant (2013) CRUK grant (2015) Wellcome Investigator Grant (2018) Professor Stockinger's laboratory investigates how environmental factors influence immune responses through the AHR pathway, with particular emphasis on intestinal immunity, inflammation, and host-microbe interactions. Her work has significant implications for understanding inflammatory bowel diseases, infection responses, and the role of dietary components in immune regulation. She has established numerous collaborations across the Francis Crick Institute and maintains active research programs examining AHR's role in both innate and adaptive immunity.

• Genome Editing
• CRISPR Technology
• Cancer Therapeutics
• +۴ مورد دیگر

Simon Liang serves as an Assistant Professor in the Department of Medicine at the University of Minnesota School of Medicine, specializing within the Gastroenterology, Hepatology, and Nutrition Division. His research integrates genome editing technologies with cancer therapeutics, focusing on ADAR1-mediated RNA editing pathways in hematologic and solid tumors. Dr. Liang's research interests center on developing CRISPR-based therapeutic strategies for cancer treatment, with particular emphasis on ADAR1 inhibition as a novel approach for acute myeloid leukemia and prostate cancer. His work bridges genome editing , epigenetic regulation , and RNA biology to address therapeutic resistance mechanisms. Key technical expertise includes prime editing optimization, CRISPR delivery systems (particularly AAV vectors), and methylation analysis. Analysis of his publication trends reveals a strategic evolution from foundational CRISPR methodology development (2019-2021) toward therapeutic applications in oncology (2022-2025), with increasing focus on translational models including non-human primates. His most impactful recent work demonstrates ADAR1's critical role in cancer cell survival across multiple malignancies. While specific awards aren't documented in the profile, his research has garnered significant attention with PlumX metrics showing: Multiple publications picked up by news outlets Substantial social media engagement (X, Bluesky) High Mendeley reader counts indicating scholarly impact Scopus citations accumulating rapidly for 2024-2025 publications Dr. Liang actively collaborates across disciplines as evidenced by co-authorship with experts in virology, oncology, and gene therapy. His work contributes to UN Sustainable Development Goals related to good health and well-being through development of precision cancer therapeutics. Current research directions include advancing prime editing for clinical translation and exploring ADAR1 inhibitors in combination therapies.